Key takeaways
Velcade (bortezomib) and bexarotene (Targretin) are both used to treat different types of cancer but work in distinct ways and have different uses. Velcade is an injectable medication used to treat multiple myeloma and mantle cell lymphoma, whereas bexarotene is taken orally to treat cutaneous T-cell lymphoma, particularly when other treatments have failed. Diarrhea, nausea, and numbness or tingling of hands or feet are common side effects of Velcade, while nerve, heart, and lung problems are possible, but rare. Common side effects of bexarotene are high fat and cholesterol levels, underactive thyroid, and weakness. Liver problems and inflammation of the pancreas are also possible. Neither medication is safe to use during pregnancy or while breastfeeding and have lower-cost generic forms available.
